
|Articles|January 1, 2008
Nomogram may predict prostate cancer recurrence at 2 years
Researchers at the University of Montreal Health Center have created a prognostic tool that fills an important gap in forecasting early recurrence of disease following radical prostatectomy.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC
2
FDA approves generic Ga-68 PSMA-11 radiodiagnostic for prostate cancer
3
FDA approves adjuvant belzutifan with pembrolizumab for ccRCC
4
Benjamin Lowentritt, MD, reviews real-world testosterone recovery data with relugolix
5











